Van Hulzen Asset Management LLC Has $2.31 Million Holdings in Abbott Laboratories $ABT

Key Points

• Van Hulzen Asset Management LLC has reduced its stake in Abbott Laboratories by 52.4%, selling 19,209 shares and holding 17,416 shares now worth approximately $2.31 million.
• Abbott Laboratories reported $1.26 earnings per share for the last quarter, meeting expectations, with revenues increasing by 7.4% year-over-year to $11.14 billion.
• The company recently declared a quarterly dividend of $0.59 per share, yielding 1.8%, with a dividend payout ratio of 29.57%.

Van Hulzen Asset Management LLC lessened its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 52.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,416 shares of the healthcare product maker's stock after selling 19,209 shares during the period. Van Hulzen Asset Management LLC's holdings in Abbott Laboratories were worth $2,310,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. Hughes Financial Services LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $27,000. Abound Financial LLC acquired a new position in Abbott Laboratories in the 1st quarter worth $28,000. Elequin Capital LP bought a new stake in Abbott Laboratories during the 1st quarter worth about $30,000. JCIC Asset Management Inc. bought a new stake in Abbott Laboratories during the 1st quarter worth about $32,000. Finally, Vision Financial Markets LLC bought a new stake in shares of Abbott Laboratories in the 1st quarter valued at about $33,000. Institutional investors own 75.18% of the company's stock.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded down $0.28 during trading hours on Tuesday, hitting $131.59. 6,076,349 shares of the stock were exchanged, compared to its average volume of 6,793,669. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company has a market cap of $229.03 billion, a PE ratio of 16.49, a price-to-earnings-growth ratio of 2.51 and a beta of 0.70. The company's fifty day simple moving average is $131.04 and its two-hundred day simple moving average is $131.33. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were given a $0.59 dividend. The ex-dividend date was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is currently 29.57%.

Analysts Set New Price Targets

ABT has been the topic of a number of research analyst reports. Wells Fargo & Company dropped their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a report on Friday, July 18th. Morgan Stanley upped their target price on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Raymond James Financial dropped their target price on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. Finally, Evercore ISI increased their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $144.47.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.